WO2006118245A1 - 皮膚再生促進剤 - Google Patents
皮膚再生促進剤 Download PDFInfo
- Publication number
- WO2006118245A1 WO2006118245A1 PCT/JP2006/308972 JP2006308972W WO2006118245A1 WO 2006118245 A1 WO2006118245 A1 WO 2006118245A1 JP 2006308972 W JP2006308972 W JP 2006308972W WO 2006118245 A1 WO2006118245 A1 WO 2006118245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin regeneration
- liquid crystal
- lyotropic liquid
- skin
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to a novel skin regeneration promoting agent that exerts an effect when applied externally.
- the skin consists of the epidermis and dermis, and the epidermis is stratified in the order of the basal layer, spiny layer, granule layer, and stratum corneum from the inside.
- the keratinocytes that make up the epidermis are metabolized (turnover) in which basal cells generated by cell division differentiate into spinous cells, granule cells, and keratinocytes in this order, and then detach as horn pieces from the surface. (The cycle is said to be 28 days with healthy skin). If this turnover is not carried out normally, it will cause various problems, such as aging of the skin and the phenomenon that melanin produced by pigment cells in the epidermis is not discharged and remains as a spot (pigmentation). Become. Therefore, it is very important from the medical and cosmetic aspects that the epidermis turnover is performed normally and the skin is always regenerated.
- dipropylendalicol dipropylendalicol, hexylenedalicol, isoparaffin, sodium lauryl sulfate, ethylene oxide adduct of lauryl alcohol, polyethylene glycol fatty acid ester
- Non-patent Document 1 and Non-patent Document 2 Polyoxyethylene sorbitan fatty acid ester, propyl carbonate, sodium pyrrolidone carboxylate, urea, lactic acid, sodium lactate, lecithin, dimethyl sulfoxide, pyrrolidone rubonic acid ester, nicotinic acid ester, N-methylproline ester, oleic acid cholesteryl ester, Amamine oxide or the like is blended into an external preparation as a transdermal absorption enhancer.
- the present inventors have energetically conducted research and development of a skin regeneration promoter. As a result, retinoic acid is encapsulated in nanometer-order capsules (nanoparticles), and the surface of the skin is encapsulated. It has been found that retinoic acid can be transdermally absorbed efficiently and in a sustained release without blending a transdermal absorption enhancer (Non-patent Document 1 and Non-patent Document 2).
- Non-Patent Document 1 New nanotechnology for transdermal delivery, Yoko Yamaguchi, Bio Bencher, IV, No. 6, pp. 62–64, 2004
- the skin regeneration-promoting agent comprising the above-mentioned retinoic acid-encapsulated nanoparticles as an active ingredient is expected to be clinically applied because it has a high effect and has little irritation to the skin of retinoic acid.
- the search for better skin regeneration promoters is meaningful.
- an object of this invention is to provide a novel skin regeneration promoter.
- lyotropic liquid crystal itself intended to be used as a base material has a skin regeneration promoting action. It was.
- lyotropic liquid crystals are known as a base material for topical medicines and cosmetics (for example, Patent No. 2547151 and Patent No. 3459253), a document describing or suggesting that lyotropic liquid crystals have an action of promoting skin regeneration. Does not exist.
- the skin regeneration-promoting agent of the present invention made based on the above findings is characterized in that, as described in claim 1, lyotropic liquid crystal is an active ingredient.
- the skin regeneration promoter according to claim 2 is the skin regeneration promoter according to claim 1, wherein the lyotropic liquid crystal contains 5 wt% to 80 wt% of a surfactant and 5 wt% to 80 wt% of water. It is characterized by that.
- the skin regeneration promoting agent according to claim 3 is characterized in that, in the skin regeneration promoting agent according to claim 2, the surfactant is a nonionic surfactant and Z or lecithin.
- the skin regeneration promoter according to claim 4 is the skin regeneration promoter according to claim 3, wherein the nonionic surfactant is a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene hydrogenated castor oil. It is characterized by at least one force selected.
- the skin regeneration-promoting agent according to claim 5 is the skin regeneration-promoting agent according to claim 2, wherein the lyotropic liquid crystal further contains 1% by weight to 80% by weight of oil.
- the skin regeneration-promoting agent according to claim 6 is characterized in that in the skin regeneration-promoting agent according to claim 5, the oil is squalane.
- the skin regeneration-promoting agent according to claim 7 is the skin regeneration-promoting agent according to claim 2, wherein the lyotropic liquid crystal further contains 1% to 55% by weight of a polyhydric alcohol.
- the skin regeneration-promoting agent according to claim 8 is the skin regeneration-promoting agent according to claim 7, characterized in that the polyhydric alcohol is glycerin.
- the skin regeneration-promoting agent according to claim 9 is characterized in that, in the skin regeneration-promoting agent according to claim 2, the lyotropic liquid crystal further contains 0.01 to 10% by weight of an auxiliary surfactant.
- the skin regeneration-promoting agent according to claim 10 is characterized in that the auxiliary surfactant is cholesterol compared to the skin regeneration-promoting agent according to claim 9.
- the skin regeneration-promoting agent according to claim 11 is the same as the skin regeneration-promoting agent according to claim 1, V, a substance having a keratinocyte separation / proliferation-promoting action on lyotropic liquid crystal, and Z or melanin pigment production inhibition.
- the skin regeneration-promoting agent according to claim 12 is characterized in that, in the skin regeneration-promoting agent according to claim 11, a substance having an action of promoting differentiation and proliferation of keratinocytes Retinal, 3-dehydr Loretinal, retinoic acid, 3-dehydroretinoic acid, retinoic acid analogue, retinoyl, retinol fatty acid ester, 3-dehydroretinol fatty acid ester power is at least one selected.
- the skin regeneration promoting agent according to claim 13 is the skin regeneration promoting agent according to claim 11, wherein the substance having a melanin pigment production inhibitory action is selected from ascorbic acid darcoside, arbutin, superoxide dismutase. It is characterized by being one.
- the skin regeneration-promoting agent according to claim 14 has a function of promoting keratinocyte separation and growth and a Z or melanin pigment production-inhibiting effect in addition to the skin regeneration-promoting agent according to claim 11. It is characterized in that the substance is blended in the form of being encapsulated inside the divalent metal inorganic acid salt fine particles.
- a skin regeneration-promoting agent as a novel medicinal use of a lyotopically picked liquid crystal that has been used as a base material for externally used pharmaceuticals and cosmetics.
- the agent exhibits an excellent inhibitory effect on skin aging and the occurrence of spots.
- skin mainly means the epidermis, but does not exclude mucous membranes.
- FIG. 1 Incorporating the retinoic acid of (A) of Example 1! / Wow! / Is a cross-sectional photograph of skin coated with lyotropic liquid crystal.
- FIG. 2 is a cross-sectional photograph of the skin coated with lyotropic liquid crystal containing retinoic acid-encapsulated nanoparticles of (B).
- FIG. 3 (C) is a cross-sectional photograph of the skin where nothing is applied.
- FIG. 4 is a graph showing changes in HB-EGF production when each of the four types of lyotropic liquid crystals in Example 2 is applied, and HB-EGF production in the skin where nothing is applied.
- FIG. 5 is a cross-sectional photograph of the skin to which each of four types of samples including a lotion containing a lyotropic liquid crystal compounded in three ratios in Example 3 and a lotion base alone are applied.
- FIG. 6 A cross-sectional photograph of the skin and the cross-section of the skin on which each of the four samples of the lyotropic liquid crystal and its constituent components, surfactant, oil, and polyhydric alcohol in Example 4 were applied. It is a photograph.
- FIG. 7 is a cross-sectional photograph of the skin to which each of four types of samples including a lotion containing lyotropic liquid crystal and a lotion base compounded in three ratios in Example 5 were applied.
- FIG. 8 is a graph showing changes over time in skin viscoelasticity when lyotropic liquid crystal is applied in Example 6.
- FIG. 9 is a photograph of the surface of keratinocytes on the skin to which two types of samples containing only a lotion containing a lyotropic liquid crystal and a lotion base in Example 7 were applied.
- FIG. 10 is a graph showing the time course of stratum corneum moisture content.
- FIG. 11 is a cross-sectional photograph of the skin coated with the lyotropic liquid crystal of Formula 1 in Example 9.
- FIG. 12 is a cross-sectional photograph of the skin to which the lyotropic liquid crystal of Formula 2 was applied.
- FIG. 13 A cross-sectional photograph of the skin with nothing applied.
- the skin regeneration-promoting agent of the present invention is characterized by comprising a lyotropic liquid crystal as an active ingredient.
- the lyotropic liquid crystal in the present invention is a coexisting system of a surfactant (an amphiphilic molecule having a hydrophilic part and a hydrophobic (lipophilic) part in the molecule) and water. It means a liquid crystal state (a state in which the molecular arrangement has a certain fluidity like a liquid while maintaining a certain regularity like a crystal) depending on the mixing ratio and temperature of the two.
- lyotropic liquid crystal water is added to a solid-state surfactant having a crystalline structure in which hydrophobic portions (hydrophobic groups such as alkyl groups) face each other in a predetermined temperature range.
- the part loses regularity due to thermal motion and becomes a liquid state, but this time the hydrophilic part acts by hydrogen bonding and maintains a long period to take an associative structure (hexagonal structure, lamellar structure, etc.) (If necessary, see “Toshiyuki Suzuki, Liquid Crystal, Vol. 2, 194–201, 1998”).
- Surfactant which is a constituent of lyotropic liquid crystal, is used in combination with water in a coexisting system with water. If it can form a liquid crystal state (especially, a periodic structure with an interplanar spacing of ⁇ ! To 800 nm is desirable) depending on the mixing ratio and temperature, it is not particularly limited.
- the surfactant may be any type of cationic, amphoteric, or amphoteric, or it may be a naturally occurring surfactant such as lecithin (egg yolk lecithin or soy lecithin) or saponin. .
- a single surfactant may be used alone, or a plurality of surfactants may be mixed and used.
- Nonionic surfactants include polyoxyethylene alkyl ether, polyoxyethylene alkyl phenol ether, alkyl darcoside, polyoxyethylene fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester Fatty acid alkanolamide, polyoxyethylene hydrogenated castor oil, and the like.
- key-on surfactants include soaps (such as sodium and potassium salts of fatty acids), alkylbenzene sulfonates (such as sodium salts), higher alcohol sulfates (such as sodium salts), and polyoxyethylene alkyl ethers.
- Cationic surfactants include alkyltrimethyl ammonium salts (such as chloride), dialkyldimethyl ammonium salts (such as chloride), alkyldimethylbenzyl ammonium salts (such as chloride), amine salts (such as chloride). Acetate, hydrochloride, etc.).
- amphoteric surfactants include alkylamino fatty acid salts (such as sodium salts), alkylbetaines, and alkylamine oxides.
- the proportion of the surfactant in the lyotropic liquid crystal is preferably 5 to 80% by weight, more preferably 7 to 70% by weight, and even more preferably 10 to 65% by weight.
- Surfactant HLB value is preferably 8 or more, more preferably 10 or more, and even more preferably 12 or more
- Distilled water or the like can be used as water as a constituent component of the lyotropic liquid crystal.
- Water may contain an organic solvent compatible with water, such as ethanol or isopropanol.
- the proportion of water in the lyotropic liquid crystal is preferably 5% to 80% by weight, more preferably 10% to 60% by weight, and even more preferably 13% to 50% by weight.
- the lyotropic liquid crystal may contain an oil component in addition to the surfactant and water. By containing oil, the liquid crystal structure approximates to the lamellar structure formed by intercellular lipids in the stratum corneum, making it easier to cause phase transition of intercellular lipid structures when applied to the skin surface. Excellent skin regeneration promoting effect.
- Oils include wheat germ oil, corn oil, castor oil, castor oil, soybean oil and other vegetable oils, silicone oil, isopropyl myristate glyceryl trioctanoate, diethylene glycol monopropylene pentaerythritol ether, and pentaerythrityl tetraocta. Ester oil such as noate, squalane
- the proportion of oil in the lyotropic liquid crystal is preferably 1 to 80% by weight, more preferably 5 to 70% by weight, and even more preferably 10 to 65% by weight.
- the lyotropic liquid crystal may contain a polyhydric alcohol.
- polyhydric alcohol such as polyethylene glycol and polyalkylene glycol, glycerin, propylene glycol, 1,3 propanediol, 2-butene 1,4-diol, pentane 1,5 diol, 2,2 dimethylpropane 1 , 3 diol, 3-methylpentane 1,5 diol, pentane 1,2 diol, 2, 2, 4 trimethylpentane 1,3 diol, 2 methylpropane 1,3 diol, hexylene glycol, 1,3 butylene glycol , Dipropylene glycol, polyethylene glycol, triethylene glycol and the like.
- a single polyhydric alcohol may be used alone, or a plurality of types may be mixed and used.
- the proportion of polyhydric alcohol in the lyotropic liquid crystal is preferably 1% to 55% by weight, more preferably 3% to 52% by weight, and further preferably 5% to 50% by weight.
- the lyotropic liquid crystal may contain cholesterol or the like as an auxiliary surfactant.
- the auxiliary surfactant even when a wide variety of surfactants are used, it is possible to reduce the curvature of the interface film, thereby facilitating the formation and stability of the liquid crystal structure.
- the proportion of the cosurfactant in the lyotropic liquid crystal is preferably 0.01% to 10% by weight.
- the lyotropic liquid crystal can be prepared by mixing a surfactant or water as its constituent components at a predetermined ratio at a predetermined temperature. If necessary, the operation may be performed when the components are heated temporarily before or after mixing.
- the skin regeneration-promoting agent of the present invention may contain a substance having a keratinocyte differentiation-promoting action or a melanin production inhibitory action in lyotropic liquid crystals.
- the skin regeneration-promoting agent of the present invention exhibits an even more excellent inhibitory effect on skin aging and the occurrence of spots.
- the compounding amount of these substances is, for example, 0.01% to 50% by weight with respect to the lyotropic liquid crystal. Retinal, 3-dehydroretinal, retinoic acid, 3-dehydroretinoic acid, retinoic acid analogs, retinol, retinol fatty acid ester, 3-dehydroretinol fatty acid ester, etc.
- substances that have keratinocyte differentiation 'proliferation promoting action are listed as substances that have keratinocyte differentiation 'proliferation promoting action. It is done.
- substances having an inhibitory action on melanin pigment production include ascorbic acid darcoside, arbutin, superoxide dismutase and the like. These substances may be blended by dispersing themselves in lyotropic liquid crystals and incorporating them between phases of the liquid crystal structure, or divalent metal inorganic acid salt fine particles, for example, having a diameter of ⁇ ! ⁇
- divalent metal inorganic acid salt fine particles for example, having a diameter of ⁇ ! ⁇
- fine particles (nanoparticles) in which these substances are encapsulated may be uniformly dispersed in lyotropic liquid crystal and incorporated between phases of the liquid crystal structure.
- lyotropic liquid crystal interfacial film
- the physical and physical stability of the substance incorporated between the phases is increased. Can be improved.
- the skin regeneration-promoting agent of the present invention contains lyotropic liquid crystal that has been used as a base material for externally used pharmaceuticals and cosmetics as an active ingredient, it may be directly applied to the skin surface as an external preparation, It may be dispersed in an ointment base, cream base or lotion base and applied to the skin surface. Needless to say, well-known ingredients such as preservatives, moisturizers and antioxidants may be appropriately added during formulation.
- Example 1 Example 1:
- a colored guinea pig with melanin-producing cells (Weiser Maples, 6 weeks old, male) is shaved, and the shaved portion is washed with lukewarm water and then washed with lukewarm water. 30 mg of was applied.
- Two days after the application date under the irradiation of either UVA, UVB, UVA or UVB the skin of the area where the lyotropic liquid crystal has been applied is collected, the slice is fixed with formalin, embedded in paraffin, and melanin It was stained by the Fontana Masson method, which dyes the pigment in black, and the skin regeneration promoting action was evaluated.
- Fig. 1 shows a cross-sectional photograph of the skin.
- FIG. 3 shows a cross-sectional photograph of the skin.
- the lyotropic liquid crystal itself showed an effect of increasing HB-EGF production, and this effect was enhanced by adding retinoic acid, regardless of the formulation.
- the lyotropic liquid crystals (a) to (u) were excellent in the storage stability of retinoic acid, and retinoic acid remained at 95% or more even after 80 days from the preparation.
- Lyotropic liquid crystal (atRAZ liquid crystal) formulated to 1%
- a lotion preparation prepared by blending the lyotropic liquid crystal of Example 1 (A) with a self-prepared lotion base (emulsion) 10%, 20%, 30% (weight ratio), and a lotion base
- the four samples of mino acids were applied on the back of the ddY mouse (5 weeks old, male) and then washed with lukewarm water at a rate of 13.5 mgZcm 2 for 4 days.
- the skin to which the sample was applied was collected on the day, and the sections were fixed with formalin, embedded in paraffin, and stained with hyaluronic acid (colloidal iron) to evaluate the skin regeneration promoting action.
- Fig. 5 shows cross-sectional photographs of the skin to which each sample was applied. As is clear from Fig. 5, the degree of thickening of the epidermis was dependent on the amount of lyotropic liquid crystal.
- Example 6 The skin regeneration promoting effect of the four types of samples was evaluated in the same manner as in Example 3 except that Ki-67 staining (a marker indicating that the cells are in a proliferative state) was used instead of hyaluronic acid staining.
- Fig. 7 shows cross-sectional photographs of the skin where each sample was applied. As is clear from FIG. 7, the number of proliferating cells is significantly increased in the skin coated with the lotion prepared by blending the lyotropic liquid crystal, which promotes skin regeneration of the lyotropic liquid crystal. It was suggested that the action was partly due to the growth promoting action on basal cells. [0028]
- Ki-67 staining a marker indicating that the cells are in a proliferative state
- Example 1 (A) Before applying the lyotropic liquid crystal of Example 1 (A) to the human (female) buttocks at a rate of lOmg / cm 2 , 30 seconds, 5 minutes, 30 minutes, 1 hour after application Later, the skin viscoelasticity was evaluated by measuring the tensile strength and the degree of return when the skin was aspirated with negative pressure (400mba) using a cute meter and then released immediately. The results are shown in FIG. As is clear from FIG. 8, by applying the lyotropic liquid crystal of Example 1 (A), the viscoelasticity of the skin decreased over time until 30 minutes after application. It increased and remained the same until 5 hours (not shown). The above results were thought to be due to skin softness caused by stratum corneum structural changes.
- a lotion preparation prepared by blending the lyotropic liquid crystal of Example 1 (A) with a self-prepared lotion base (emulsion) at a ratio (weight ratio) of 30%, and two types of samples containing only the lotion base, After applying an appropriate amount to the human (female) buttocks for 1 month, the skin keratinocytes of the part applied by the tape split method were transferred and stained with a mixed solution of gentian violet and brilliant green.
- Fig. 9 shows a photograph of the surface of the keratinocytes of the skin where each sample was applied. As can be seen from Fig.
- Fig. 10 shows changes over time in the stratum corneum moisture content of the skin where each of the two types of samples measured using a cut meter was applied. As can be seen, the stratum corneum water content increased markedly when a lotion preparation prepared by blending lyotropic liquid crystals was applied, compared to the case where only the lotion base was applied.
- the lyotropic liquid crystal of (A) of Example 1 was blended with a commercially available lotion base at a ratio of 30% (weight ratio), and ascorbic acid darcoside having a whitening effect and a melanin pigment production inhibitory effect was ratio of 2% (weight ratio).
- lotion preparation prepared with ascorbic acid Apply two samples of lotion preparations prepared by blending only dalcoside at a ratio of 2% (weight ratio) to the human (female) buttocks for 2 months, and then apply each sample.
- a lotion preparation prepared by blending lyotropic liquid crystal and ascorbate darcoside was compared with the case where a lotion preparation prepared by combining only ascorbic acid dalcoside was applied.
- the brightness of the skin increased.
- L * value when the change in lightness of the skin was evaluated by L * value, when a lotion prepared with only ascorbic acid glucoside was applied, it was 57.43 before application. After application, there was little change to 56.48, but when a lotion prepared with lyotropic liquid crystal and ascorbic acid darcoside was applied, it was 5 7.59 before application. After painting, it increased to 60.34 (the larger the L * value, the more judged white).
- Table 1 Four types of formulations (unit:% by weight) listed in Table 1 were prepared by mixing the constituents. Specifically, after mixing all ingredients except distilled water, heat to about 60 ° C to melt soybean lecithin, cholesterol, POE (60) hydrogenated castor oil, and then add a predetermined amount of distilled water. It was prepared by adding and stirring.
- FIGS. 11 to 13 shows a cross-sectional photograph of the skin to which nothing was applied.
- the lyotropic liquid crystal of Formula 1 and Treatment 2 when the lyotropic liquid crystal of Formula 1 and Treatment 2 is applied, the thickening of the epidermis is more remarkable than the control, and the skin regeneration promoting action is excellent, and the melanin pigment is better than the control. The amount was too small.
- a commercial preservative was added to the lyotropic liquid crystal of Formula 1 of Example 9 to prepare a formulation.
- the lyotropic liquid crystal of Formula 2 of Example 9 was blended with a self-prepared lotion base (milky lotion), and a commercially available antiseptic was added to formulate a lotion.
- the lotion base was prepared by mixing and emulsifying soy lecithin, cholesterol, PEG4000, cyclic silicone, carbopol (polymer gelling agent), celtrol (polymer gelling agent), and distilled water.
- the present invention is industrially applicable in that it can provide a skin regeneration promoter as a novel pharmaceutical use of lyotropic liquid crystal, which has been used as a base material for externally used pharmaceuticals and cosmetics.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06745831A EP1878420A4 (en) | 2005-04-28 | 2006-04-28 | SKIN REGENERATION ACTIVATOR |
US11/912,959 US20090017123A1 (en) | 2005-04-28 | 2006-04-28 | Dermal regeneration enhancer |
CA002607765A CA2607765A1 (en) | 2005-04-28 | 2006-04-28 | Dermal regeneration enhancer |
CN2006800190334A CN101184469B (zh) | 2005-04-28 | 2006-04-28 | 皮肤再生促进剂 |
JP2007514832A JP5271538B2 (ja) | 2005-04-28 | 2006-04-28 | 皮膚再生促進剤 |
US12/818,869 US20100305215A1 (en) | 2005-04-28 | 2010-06-18 | Dermal regeneration enhancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-130971 | 2005-04-28 | ||
JP2005130971 | 2005-04-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/818,869 Continuation US20100305215A1 (en) | 2005-04-28 | 2010-06-18 | Dermal regeneration enhancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006118245A1 true WO2006118245A1 (ja) | 2006-11-09 |
Family
ID=37308039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/308972 WO2006118245A1 (ja) | 2005-04-28 | 2006-04-28 | 皮膚再生促進剤 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20090017123A1 (ja) |
EP (1) | EP1878420A4 (ja) |
JP (1) | JP5271538B2 (ja) |
KR (1) | KR20080010443A (ja) |
CN (1) | CN101184469B (ja) |
CA (1) | CA2607765A1 (ja) |
TW (1) | TW200716193A (ja) |
WO (1) | WO2006118245A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007308668A (ja) * | 2005-06-06 | 2007-11-29 | Konica Minolta Holdings Inc | 液晶組成物およびこれを用いた液晶表示素子 |
WO2008050844A1 (fr) * | 2006-10-27 | 2008-05-02 | Taisho Pharmaceutical Co., Ltd. | Composition pour une application externe sur la peau et promoteur de la régénération de la peau |
WO2009096481A1 (ja) * | 2008-01-30 | 2009-08-06 | Tbc Group Co., Ltd. | 皮膚外用組成物および美白化粧料 |
JP2009286770A (ja) * | 2008-06-02 | 2009-12-10 | Noevir Co Ltd | 液状油の皮膚の柔らかくする効果の評価方法並びに該液状油を含有する皮膚外用剤及びその製造方法 |
WO2012137500A1 (ja) * | 2011-04-05 | 2012-10-11 | 株式会社ナノエッグ | メラニン色素排出用組成物 |
JPWO2012165468A1 (ja) * | 2011-05-31 | 2015-02-23 | 株式会社ナノエッグ | 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物 |
WO2019150375A1 (en) * | 2018-02-05 | 2019-08-08 | Dermafence Ltd. | Methods and compositions for treating and preventing skin barrier disruptions |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2594629A4 (en) | 2010-07-16 | 2016-05-11 | Fujikura Ltd | BASE BODY AND METHOD FOR PRODUCING THE BASE BODY |
CN102526745B (zh) * | 2012-02-02 | 2013-02-27 | 西安交通大学 | 一种用微电场控制溶致液晶担载药物分子的缓释方法 |
CN103494714B (zh) * | 2013-10-16 | 2015-10-28 | 广东轻工职业技术学院 | 一种能形成液晶结构的乳化剂组合物及应用 |
CN103690450B (zh) * | 2013-12-20 | 2016-04-20 | 中兴能源(天津)有限公司 | 具有美白抗衰老功效的组合物、护肤品及制备方法与应用 |
KR102645439B1 (ko) | 2018-11-09 | 2024-03-11 | (주)아모레퍼시픽 | 아우레오바시디움 풀루란스 균주의 배양물 또는 추출물을 포함하는 저자극 피부 재생 또는 피부 진정용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11506125A (ja) * | 1996-03-05 | 1999-06-02 | ザ、プロクター、エンド、ギャンブル、カンパニー | スキンケア組成物 |
KR20010011004A (ko) * | 1999-07-24 | 2001-02-15 | 서경배 | 농도전이형 액정형성화합물 및 이의 제조방법 |
KR20010098134A (ko) * | 2000-04-28 | 2001-11-08 | 서경배 | 농도 전이형 액정형성화합물 및 이의 제조방법, 및 이를함유하는 화장료 조성물 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH18145A (en) * | 1982-07-07 | 1985-04-03 | Unilever Nv | Hair conditioning preparation |
HU209605B (en) * | 1991-04-15 | 1994-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for production of wather-free transdermal preparation |
GB9207191D0 (en) * | 1992-04-01 | 1992-05-13 | Unilever Plc | Cosmetic compositions |
JPH0818950B2 (ja) * | 1992-05-01 | 1996-02-28 | 花王株式会社 | 化粧料 |
GB9312100D0 (en) * | 1993-06-11 | 1993-07-28 | Procter & Gamble | Cosmetic make-up compositions |
US5688831A (en) * | 1993-06-11 | 1997-11-18 | The Procter & Gamble Company | Cosmetic make-up compositions |
DE4320119A1 (de) * | 1993-06-18 | 1994-12-22 | Henkel Kgaa | Flüssigkristalline wäßrige Tensidzubereitung |
JPH0899856A (ja) * | 1994-09-29 | 1996-04-16 | Shiseido Co Ltd | 皮膚外用剤 |
GB9420535D0 (en) * | 1994-10-12 | 1994-11-30 | Procter & Gamble | Cosmetic make-up compositions |
US5871760A (en) * | 1994-11-28 | 1999-02-16 | The Procter & Gamble Company | Skin care compositions |
US6224888B1 (en) * | 1999-02-12 | 2001-05-01 | The Procter & Gamble Company | Cosmetic compositions |
JP4036560B2 (ja) * | 1999-02-23 | 2008-01-23 | 三菱鉛筆株式会社 | 液体化粧料 |
US6238653B1 (en) * | 1999-12-22 | 2001-05-29 | Revlon Consumer Products Corporation | Liquid crystalline peroxide compositions and methods for coloring and/or bleaching hair |
JP4880816B2 (ja) * | 2000-12-15 | 2012-02-22 | 株式会社ヤクルト本社 | 皮膚老化防止剤 |
JP2002348234A (ja) * | 2001-05-28 | 2002-12-04 | Purotekku:Kk | 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤 |
EP1509192A1 (en) * | 2002-06-04 | 2005-03-02 | The Procter & Gamble Company | Conditioning shampoo composition containing select cationic conditioning polymers |
CA2524589A1 (en) * | 2003-05-07 | 2004-11-18 | Ifac Gmbh & Co. Kg | Compositions for the targetted release of fragrances and aromas |
CN1859905A (zh) * | 2003-10-15 | 2006-11-08 | 日本株式会社Ltt生物医药 | 多价金属无机盐包覆的视黄酸纳米颗粒的粒径的调节方法和由该调节方法得到的纳米颗粒 |
US20070243144A1 (en) * | 2004-10-07 | 2007-10-18 | Toyo Shinyaku Co., Ltd | External Preparation |
KR101329907B1 (ko) * | 2005-04-28 | 2013-11-14 | 가부시키가이샤 나노에그 | 경피 흡수 촉진제 |
-
2006
- 2006-04-28 JP JP2007514832A patent/JP5271538B2/ja active Active
- 2006-04-28 EP EP06745831A patent/EP1878420A4/en not_active Withdrawn
- 2006-04-28 TW TW095115305A patent/TW200716193A/zh unknown
- 2006-04-28 CA CA002607765A patent/CA2607765A1/en not_active Abandoned
- 2006-04-28 WO PCT/JP2006/308972 patent/WO2006118245A1/ja active Application Filing
- 2006-04-28 US US11/912,959 patent/US20090017123A1/en not_active Abandoned
- 2006-04-28 CN CN2006800190334A patent/CN101184469B/zh active Active
- 2006-04-28 KR KR1020077027690A patent/KR20080010443A/ko not_active Application Discontinuation
-
2010
- 2010-06-18 US US12/818,869 patent/US20100305215A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11506125A (ja) * | 1996-03-05 | 1999-06-02 | ザ、プロクター、エンド、ギャンブル、カンパニー | スキンケア組成物 |
KR20010011004A (ko) * | 1999-07-24 | 2001-02-15 | 서경배 | 농도전이형 액정형성화합물 및 이의 제조방법 |
KR20010098134A (ko) * | 2000-04-28 | 2001-11-08 | 서경배 | 농도 전이형 액정형성화합물 및 이의 제조방법, 및 이를함유하는 화장료 조성물 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007308668A (ja) * | 2005-06-06 | 2007-11-29 | Konica Minolta Holdings Inc | 液晶組成物およびこれを用いた液晶表示素子 |
WO2008050844A1 (fr) * | 2006-10-27 | 2008-05-02 | Taisho Pharmaceutical Co., Ltd. | Composition pour une application externe sur la peau et promoteur de la régénération de la peau |
WO2009096481A1 (ja) * | 2008-01-30 | 2009-08-06 | Tbc Group Co., Ltd. | 皮膚外用組成物および美白化粧料 |
JP2009286770A (ja) * | 2008-06-02 | 2009-12-10 | Noevir Co Ltd | 液状油の皮膚の柔らかくする効果の評価方法並びに該液状油を含有する皮膚外用剤及びその製造方法 |
WO2012137500A1 (ja) * | 2011-04-05 | 2012-10-11 | 株式会社ナノエッグ | メラニン色素排出用組成物 |
JPWO2012165468A1 (ja) * | 2011-05-31 | 2015-02-23 | 株式会社ナノエッグ | 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物 |
WO2019150375A1 (en) * | 2018-02-05 | 2019-08-08 | Dermafence Ltd. | Methods and compositions for treating and preventing skin barrier disruptions |
JP2021512177A (ja) * | 2018-02-05 | 2021-05-13 | デルマフェンス リミテッド | 皮膚バリア破壊の治療および予防のための方法および組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP5271538B2 (ja) | 2013-08-21 |
CN101184469B (zh) | 2011-08-24 |
TW200716193A (en) | 2007-05-01 |
US20090017123A1 (en) | 2009-01-15 |
KR20080010443A (ko) | 2008-01-30 |
EP1878420A1 (en) | 2008-01-16 |
US20100305215A1 (en) | 2010-12-02 |
TWI367106B (ja) | 2012-07-01 |
JPWO2006118245A1 (ja) | 2008-12-18 |
EP1878420A4 (en) | 2009-08-12 |
CN101184469A (zh) | 2008-05-21 |
CA2607765A1 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5271538B2 (ja) | 皮膚再生促進剤 | |
KR101329907B1 (ko) | 경피 흡수 촉진제 | |
Clares et al. | Nanoemulsions (NEs), liposomes (LPs) and solid lipid nanoparticles (SLNs) for retinyl palmitate: Effect on skin permeation | |
Manosroi et al. | Transdermal absorption enhancement of papain loaded in elastic niosomes incorporated in gel for scar treatment | |
van Hoogevest et al. | Phospholipids in cosmetic carriers | |
JP4203394B2 (ja) | 高濃度のトリテルペノイドを含有する微小化リポソーム及びその製造方法 | |
KR100394770B1 (ko) | 토코페롤 유도체를 이용하여 나노유화입자를 안정화시키는방법 및 나노유화입자를 함유하는 피부 외용제 조성물 | |
US20050232953A1 (en) | Microemulsions having a binary phase differentiability and active substance differentiability, the production thereof and their use, particularly for the topical supply of oxygen | |
Mishra et al. | Potential of nanoparticulate based delivery systems for effective management of alopecia | |
CN112891241A (zh) | 一种靶向线粒体皮肤抗衰纳米组合物及其制备方法和应用 | |
US20210346458A1 (en) | Compositions and methods for improving bruising and rejuvenating skin | |
Aparajita et al. | Liposomes as carriers in skin ageing | |
KR101176523B1 (ko) | 성상 변화를 갖는 화장료 조성물 | |
WO2022155656A1 (en) | Cosmetic compositions | |
JP2010229117A (ja) | 皮膚外用剤 | |
US9173940B1 (en) | Mixture of betamethasone and tranilast with a transdermal gel for scar treatment | |
KR102217745B1 (ko) | 피부흡수 촉진용 탄성 리포좀 조성물, 이를 포함하는 피부흡수 촉진용 탄성 리포좀 및 이의 제조방법 | |
JP2000159656A (ja) | コラーゲン合成促進剤 | |
JP3834563B2 (ja) | アルブチンを利用した安定なナノ乳化粒子の製造方法及びナノ乳化粒子を含有する化粧料組成物 | |
JP2011207849A (ja) | 口唇用化粧料 | |
JP5756602B2 (ja) | ゼラチンおよび/またはエラスチン構成ポリペプチドで修飾されたリポソームからなる化粧料基剤およびそれを含有する皮膚化粧料 | |
KR20090028275A (ko) | 에센셜 오일 조합을 주성분으로 하는피부 노화방지와주름개선 효과를 갖는 화장료 및 그 제조방법 | |
KR20240009259A (ko) | 부착능 강화를 통한 피부 흡수 및 효능 증강 리포좀 조성물 및 그의 제조방법 | |
WO2010137335A1 (ja) | α-リポ酸ナノ粒子を含有する、ターンオーバー促進用組成物 | |
WO2009096481A1 (ja) | 皮膚外用組成物および美白化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680019033.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007514832 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2607765 Country of ref document: CA Ref document number: 11912959 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006745831 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077027690 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006745831 Country of ref document: EP |